Select a State

Global health R&D delivers for Indiana

US government investment in global health R&D has delivered

$48.8 million
to Indiana research institutions
600+ new jobs
for Indiana

Neglected diseases in Indiana

Chikungunya cases
43
Dengue cases
44
HIV diagnoses
4,229
Malaria cases
123
Tuberculosis cases
956
West Nile cases
179
Zika cases
52

Indiana's top USG-funded global health R&D institutions

University of Notre Dame
$26.2 million
Indiana University-Purdue University at Indianapolis
$10.3 million
Purdue University
$7.9 million
Indiana University Bloomington
$3.8 million
Butler University
$306 thousand
Earlham College
$219 thousand

Indiana industry in global health R&D

AstraZeneca
Location(s):
Mount Vernon
Bayer
Location(s):
Mishawaka
Beckman Coulter
Location(s):
Indianapolis
Eli Lilly and Company
Location(s):
Indianapolis
Roche
Location(s):
Indianapolis

Indiana's top areas of global health R&D by USG funding

3.6%
HIV/AIDS
38.2%
Malaria
25.1%
Tuberculosis
5.2%
Salmonella infections
23.0%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Trachoma
4.8%
Other
Bacteria pneumonia & meningitis
Non-allocable

Global health R&D at work in Indiana

University of Notre Dame researchers are studying the use of spatial repellents to prevent mosquito-borne diseases. Spatial repellents release chemicals (a common example is a mosquito candle) and can help stop the spread of disease where existing tools such as bednets and indoor residual spraying are not entirely effective. New strategies are needed to avert the more than 50 million cases of dengue and 200 million cases of malaria that occur each year. The project will generate data to inform disease control programs.

Footnotes